Are you passionate about the legalization of psychedelics?
Come learn from leading experts about the latest in the movement to decriminalize and legalize psychedelics—and how you can get involved. There’s been a lot of momentum in the last year or so, from Trump signing an executive order to fast-track certain psychedelics to New Mexico legalizing psilocybin therapy. Recently, the largest pharmaceutical company in the world also acquired a smaller psychedelic pharma company in large part for their 5-MeO-DMT nasal spray.
Alongside this momentum, churches continue to seek exemption to serve psychedelics as sacraments—although many of them are making dubious claims about their legality—and a booming gray market is selling psychedelic products, claiming that they’re allowed to do so, because their jurisdictions have decriminalized (that’s not true either).
Robert T. Rush
Robert T. Rush is an attorney whose practice focuses on controlled-substances law, psychedelic and cannabis regulation, administrative law, and complex litigation. He is the founder of the Rights and Reason Project, a nonprofit legal and advocacy organization dedicated to protecting scientific research, challenging unjustified drug scheduling, and defending cognitive liberty, bodily autonomy, and religious freedom.
Through the Law Office of Robert T. Rush, Rush represents researchers, businesses, nonprofit organizations, religious organizations, therapists, advocates, and individuals navigating the rapidly evolving legal landscape surrounding psychedelics, cannabis, and other controlled substances. His work includes federal Controlled Substances Act matters, federal Analogues Act analysis, DEA scheduling and rulemaking proceedings, Administrative Procedure Act challenges, religious-use and RFRA matters, regulatory compliance, and strategic litigation involving emerging areas of drug policy.
Rush has played a leading role in challenges to federal efforts to place research compounds into Schedule I, including litigation opposing the scheduling of DOI and
Sam Chapman
Sam Chapman is one of the country’s leading experts on state-based psychedelic policy and access programs. He served as Campaign Manager for Oregon’s Measure 109, the nation’s first successful ballot measure to create a legal framework for psilocybin therapy, and later helped guide implementation efforts in Oregon and Colorado. Over the past decade, Sam has advised lawmakers, regulators, advocates, and philanthropists across the country on psychedelic policy reform.
In 2025, Sam founded the Center for Psychedelic Policy (CPP) to solve one of the most urgent and overlooked challenges in the field: affordability. CPP is a 501(c)(3) nonprofit organization. Under Sam’s leadership, the Center launched the National Psychedelic Landscape Assessment (NPLA), the first comprehensive analysis of state legislation and policy trends focused on access, implementation, and public investment.
Sam’s work is grounded in a belief that real-world healing requires real-world access, and that affordability must be the foundation of any scalable policy model. He regularly partners with legislators, funders, and researchers to design pragmatic strategies that work in today’s political environment.
Jack is the founder of Psychedelic State(s) of America – a nonprofit-sponsored news organization dedicated to rigorous independent psychedelic journalism. Learn more about PSA and donate to the PSA Media Fund here.
Shelby Hartman is Co-Founder and Publisher of DoubleBlind, a media company at the forefront of the psychedelic movement. She’s reported for the Los Angeles Times, Rolling Stone, VICE, Playboy, Quartz, LA Weekly, and the Huffington Post, among others. Her work has been featured in outlets such as The New York Times, Business Insider, KCRW, Bustle, and Forbes, and she’s been invited to speak at SXSW, Horizons: Perspectives in Psychedelics, and Harvard Law School. She’s the co-author of The DoubleBlind Guide to Psychedelics (Hachette, 2026), a practical guide on how to trip situated within reporting about the psychedelic ecosystem. In 2020, she was named by Forbes as a female leader in cannabis and psychedelics. She’s a graduate of Columbia Journalism School.
Federal Drug Policy, April 2026: The Operative Architecture of Cannabis Rescheduling, the Psychedelic Therapeutic Acceleration Directive, and the Road to June 29 RN...
